Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions. The APTIMA HPV assay is an amplified nucleic acid test for 14 high-risk HPV types that are associated with cervical cancer. The test would be run on its TIGRIS fully automated system that is being used today in 200 U.S. clinical laboratories to test for chlamydia and gonorrhea. Based upon similar PMA submissions the APTIMA test could be cleared through the FDA by year-end 2011. The global market for HPV tests is in the range of $350M of which 80% is in the U.S. The competitors are Qiagen(QGEN),Hologic (HOLX) and Roche (ROG.VX).
- Groups sue over Alabama abortion law; judge blocks Mississippi ban May 25, 2019
- Mexico budget cuts hit patient care and delay kids' surgeries, doctors warn May 24, 2019
- Novartis $2 million gene therapy for rare disorder is world's most expensive drug May 24, 2019
- Doctor, medical funder charged in New York in transvaginal mesh fraud May 24, 2019
2009-2017 Life Science Portfolios 2018 Rayno Biopharmaceuticals Portfolio 2018 Rayno Tools and Diagnostics Portfolio BIOgraph Biopharmaceuticals Clinical Diagnostics and Tools Energy Life Science ETF's and Mutual Funds Macro RAG Rayno Life Science Portfolio Reading List Weather//Ski Reports-Western US Weather Snow Reports West Coast